Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Instrumentation Metrics' Noninvasive Glucose Monitor Pivotal Study Planned

This article was originally published in The Gray Sheet

Executive Summary

Instrumentation Metrics will complete a clinical trial later in March for its IM200 noninvasive glucose monitor in anticipation of a 300 to 400-patient, multi-center pivotal study. The Chandler, Arizona firm plans to submit a premarket approval application for the device in late 2002 or early 2003.

You may also be interested in...



Financings In Brief

SonoSite: Handheld digital ultrasound device manufacturer plans secondary offering of 2.7 mil. shares of common stock. Assuming a public offering price of $22.95 per share, estimated net proceeds would be about $57.8 mil., according to a Feb. 22 prospectus filed with the Securities and Exchange Commission. The funds will be used for general corporate purposes, which may include expanded sales and marketing efforts for the SonoSite 180Plus and SonoHeart Elite ultrasound devices, as well as expanded manufacturing, R&D and potential acquisitions, SonoSite says. The Bothell, Washington firm has granted managing underwriters UBS Warburg and Deutsche Banc Alex. Brown the option to purchase an additional 405,000 shares to cover any over allotments, which could boost net proceeds to $66.5 mil., according to SonoSite...

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel